About SAIC Frederick

SAIC-Frederick, a wholly owned subsidiary of SAIC, is helping to speed the delivery of new technologies and treatments to patients with cancer and AIDS.

SAIC-Frederick operates the laboratories at the National Cancer Institute at Frederick (NCI-Frederick).

SAIC-Frederick's staff of more than 1,700 scientific, technical, and support professionals conducts basic and applied research in cancer and AIDS, operates and manages the federal government's only vaccine manufacturing facilities (Vaccine Pilot Plant, Biopharmaceutical Development Program), operates the high-performance Advanced Biomedical Computing Center, and supports more than 300 clinical trials treating patients in the United States and around the world.

The company also manages public-private partnerships for the government and makes research and development technologies available on a limited, fee-for-service basis to other government agencies through the Economy Act and to academic institutions and corporate entities through a Work for Others program.

---

---

A Federally Funded Research and Development Center (FFRDC)

NCI-Frederick is one of only 38 facilities designated by Congress as a Federally Funded Research and Development Center (FFRDC). These are government-owned, contractor-operated entities best known as the national laboratories at Brookhaven, Argonne, Sandia, Oak Ridge, Los Alamos, and elsewhere.

The FFRDC is a special business model defined under government regulations that require the contractor to be autonomous, or a separate operating unit of a parent company, and to operate in the public interest. It also permits special access to privileged government information and facilities, and it allows broad latitude in subcontracting.

Authorities granted to the FFRDC guarantee flexibility, efficiency, rapid response, and accountability. This enables the FFRDC to respond rapidly to new and emerging mission-critical initiatives of NCI and to manage public-private partnerships that accelerate the delivery of new treatments to cancer patients.